This inventor holds 2 USPTO granted patents. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of Marc Kerenyi
Introduction
Marc Kerenyi is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that serve as inhibitors for specific cancer-related proteins. With a total of 2 patents, Kerenyi's work is focused on advancing therapeutic options for oncological diseases.
Latest Patents
Kerenyi's latest patents include innovative compounds that target CDK8 and CDK19, which are crucial in the regulation of cell cycle and transcription. The first patent involves [1,6]naphthyridine compounds and derivatives, which are designed to act as inhibitors of CDK8/19. These compounds are formulated for use in pharmaceutical compositions aimed at treating and preventing oncological diseases. The second patent focuses on phenylpyrazolylacetamide compounds and derivatives, also serving as CDK8/19 inhibitors, with similar applications in the medical field.
Career Highlights
Marc Kerenyi is currently employed at Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His work at this esteemed organization allows him to collaborate with other talented professionals in the field, contributing to groundbreaking research and development.
Collaborations
Kerenyi has worked alongside notable colleagues such as Harald Engelhardt and Marco Hans Hofmann. These collaborations have fostered an environment of innovation and creativity, leading to the development of impactful medicinal compounds.
Conclusion
Marc Kerenyi's contributions to the field of medicinal chemistry are noteworthy, particularly in the development of CDK8/19 inhibitors. His work at Boehringer Ingelheim International GmbH and his collaborations with esteemed colleagues highlight his commitment to advancing cancer treatment options.